BUSINESS INFORMATION REPORT
1. Summary Information
|
|
|
Country |
India |
|
Company Name |
Akums Drugs And Pharmaceuticals Limited |
Principal Name 1 |
Mr. Dharam Chand Jain |
|
Status |
Good |
Principal Name 2 |
Mr. Sanjeev Jain |
|
|
|
Registration # |
55-125888 |
|
Street Address |
304, |
||
|
Established Date |
19.04.2004 |
SIC Code |
-- |
|
Telephone# |
91-11-27011428 |
Business Style 1 |
Manufacturer |
|
Fax # |
91-11-27023256 |
Business Style 2 |
Supplier |
|
Homepage |
Product Name 1 |
Pharmaceutical
Machinery |
|
|
# of employees |
-- |
Product Name 2 |
- |
|
Paid up capital |
Rs.11,750,000 |
Product Name 3 |
- |
|
Shareholders |
Directors
or relatives of directors -100% |
|
|
|
Public Limited Corp. |
NO |
Business Period |
7 years |
|
IPO |
NO |
International Ins. |
- |
|
Public |
NO |
Rating |
A (58) |
|
Related
Company |
|||
|
Relation
|
Country
|
Company
Name |
CEO |
|
Associates/Subsidiaries |
India |
Welcure Drugs and Pharmaceuticals Limited |
-- |
|
Note |
- |
||
2. Summary
Financial Statement
|
Balance Sheet as of |
31.03.2010 |
(Unit: Indian Rs.) |
|
|
Assets |
Liabilities |
||
|
Current Assets |
1,399,149,000 |
Current Liabilities |
715,079,000 |
|
Inventories |
740,858,000 |
Long-term Liabilities |
912,451,000 |
|
Fixed Assets |
1,778,659,000 |
Other Liabilities |
123,166,000 |
|
Deferred Assets |
0 |
Total Liabilities |
1,750,696,000 |
|
Invest& other Assets |
9,318,000 |
Retained Earnings |
2,165,538,000 |
|
|
|
Net Worth |
2,177,288,000 |
|
Total Assets |
3,927,984,000 |
Total Liab. & Equity |
3,927,984,000 |
|
Total Assets (Previous Year) |
3,393,557,000 |
|
|
|
P/L Statement as of |
31.03.2010 |
(Unit: Indian Rs.) |
|
|
Sales |
4,109,311,000 |
Net Profit |
402,976,000 |
|
Sales(Previous yr) |
3,285,793,000 |
Net Profit(Prev.yr) |
436,235,000 |
MIRA
INFORM REPORT
|
Report Date : |
10.09.2011 |
IDENTIFICATION DETAILS
|
Name : |
AKUMS DRUGS AND PHARMACEUTICALS LIMITED |
|
|
|
|
Registered Office : |
304, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.03.2010 |
|
|
|
|
Date of Incorporation : |
19.04.2004 |
|
|
|
|
Com. Reg. No.: |
55-125888 |
|
|
|
|
Capital Investment / Paid-up Capital : |
Rs.11.750 Millions |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24239DL2004PLC125888 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
DELA13882B |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AAECA7090B |
|
|
|
|
Legal Form : |
A Closely held Public Limited Liability Company |
|
|
|
|
Line of Business : |
Manufacturer and Supplier of Pharmaceutical Machinery. |
|
|
|
|
No of Employees : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
A (58) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
USD 8700000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a well established and a reputed company having fine track.
Financial positions of the company appears to be sound. Trade relations are
reported as fair. Business is active. Payments are reported to be regular and
as per commitments. The company can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – April 1, 2010
|
Country Name |
Previous Rating (31.12.2009) |
Current Rating (01.04.2010) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered Office : |
304, |
|
Tel. No.: |
91-11-47511000 (30 lines) |
|
Fax No.: |
91-11-27023256 |
|
E-Mail : |
|
|
Website : |
|
|
|
|
|
Manufacturing Unit I |
19-20-21, Sector-6A, I.I.E., SIDCUL, Ranipur,
Haridwar-249403, Uttarakhand |
|
Tel. No.: |
91-1334-239220 – 224, 325982, 84, 85,86 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
Website : |
www.akums.com |
|
|
|
|
Manufacturing Unit II |
22, Sector-6A, IIE, SIDCUL, Ranipur, Haridwar - -249403
Uttarakhand |
|
Tel. No.: |
91-1334-239220 – 224, 325982, 84 ,85, 86 |
|
Fax No.: |
91-1334-239219 |
|
E-Mail : |
|
|
|
|
|
Manufacturing Unit III |
2,3,4,5 Sector-6B, IIE, SIDCUL, Ranipur, Haridwar -249403
Uttarakhand |
|
Tel. No.: |
91-1334- 237100 – 104 |
|
Fax No.: |
91-1334-237105 |
|
E-Mail : |
|
|
Website : |
www.akums.com |
|
|
|
|
Manufacturing Unit IV : |
47, Sector 6B, SIDCUL, Ranipur, Haridwar -249403
Uttarakhand |
|
|
|
|
Manufacturing Unit V : |
48, Sector 6B, SIDCUL, Ranipur, Haridwar -249403
Uttarakhand |
DIRECTORS
AS ON 27.09.2010
|
Name : |
Mr. Sanjeev Jain |
|
Designation : |
Whole-Time Director |
|
Address : |
E -1052, Saraswati Vihar, |
|
Date of Birth : |
11.04.1956 |
|
Date of Appointment : |
19.04.2004 |
|
DIN No.: |
00323433 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of appointment
at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U74899DL1986PTC025186 |
WELCURE
PHARMACEUTICALS PRIVATE LIMITED |
Director |
21-08-86 |
21-08-86 |
- |
Active |
NO |
|
2 |
U85195DL1987PLC194421 |
A.K.
LABORATORIES LIMITED |
Director |
01-04-93 |
01-04-93 |
01-06-07 |
Active |
NO |
|
3 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Whole-time
director |
01-06-07 |
19-04-04 |
- |
Active |
NO |
|
4 |
L24232RJ1996PLC012418 |
WELCURE DRUGS
AND PHARMACEUTICALS LTD. (TRANSFER FROM |
Whole-time
director |
01-04-05 |
01-04-05 |
01-06-07 |
Active |
NO |
|
5 |
U72900DL2010PLC206414 |
AKUMENTIS
HEALTHCARE LIMITED |
Director |
29-07-10 |
29-07-10 |
14-10-10 |
Active |
NO |
|
Name : |
Mr. Mata Pher Singh |
|
Designation : |
Whole Time Director |
|
Address : |
Plot No. 19, 20, 21 Sector 6A, II, E, SIDCUL, Haridwar – 249 403, |
|
Date of Birth : |
20.06.1957 |
|
Date of Appointment : |
23.05.2004 |
|
DIN No.: |
00356220 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U99999DL1998PLC095297 |
AMAZING RESEARCH
LABORATORIES LIMITED |
Director |
23-11-01 |
23-11-01 |
21-10-07 |
Active |
NO |
|
2 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Whole-time
director |
01-09-05 |
23-05-04 |
- |
Active |
NO |
|
Name : |
Mr. Sandeep Jain |
|
Designation : |
Whole-Time Director |
|
Address : |
E -1052, Saraswati Vihar, |
|
Date of Birth : |
05.08.1967 |
|
Date of Appointment : |
19.04.2004 |
|
DIN No.: |
00323476 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U85195DL1987PLC194421 |
A.K.
LABORATORIES LIMITED |
Director |
01-04-93 |
01-04-93 |
01-06-07 |
Active |
NO |
|
2 |
U74899DL1986PTC025186 |
WELCURE
PHARMACEUTICALS PRIVATE LIMITED |
Director |
04-10-99 |
04-10-99 |
- |
Active |
NO |
|
3 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Whole-time
director |
01-06-07 |
19-04-04 |
- |
Active |
NO |
|
4 |
L24232RJ1996PLC012418 |
WELCURE DRUGS
AND PHARMACEUTICALS LTD. (TRANSFER FROM |
Whole-time
director |
01-08-04 |
01-08-04 |
01-06-07 |
Active |
NO |
|
5 |
U74899DL1994PLC057323 |
MAXCURE DRUGS
AND PHARMACEUTICALS LIMITED |
Additional
director |
02-02-10 |
02-02-10 |
- |
Active |
NO |
|
Name : |
Mr. Narendra Dev Sachdeva |
|
Designation : |
Whole Time
Director |
|
Address : |
40/22, IIIrd Floor, C R Park, |
|
Date of Birth : |
15.10.1960 |
|
Date of Appointment : |
27.08.2004 |
|
DIN No: |
00330005 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Whole-time
director |
01-09-05 |
27-08-04 |
- |
Active |
NO |
|
Name : |
Mr. Santosh Kumar Talwar |
|
Designation : |
Additional Director |
|
Address : |
A 603, Divya Apartment, Sector 10, Plot 21, Dwarka, New Delhi-110066, |
|
Date of Birth : |
08.08.1945 |
|
Date of Appointment : |
01.06.2008 |
|
DIN No.: |
02103812 |
Other Directorship
|
S.No. |
CIN |
Name of the
Company |
Current
designation of the director |
Date of
appointment at current designation |
Original date of
appointment |
Date of
cessation |
Company Status |
Defaulting
status |
|
1 |
U24239DL2004PLC125888 |
AKUMS DRUGS AND
PHARMACEUTICALS LIMITED |
Additional
director |
01-06-08 |
01-06-08 |
- |
Active |
NO |
KEY EXECUTIVES
|
Name : |
Mr. Amit Yadav |
|
Designation : |
Secretary |
|
Address : |
3853, Mandir Stret, Pahari dhiraj, delhi-110006, |
|
Date of Birth/Age : |
12.11.1981 |
|
Date of Appointment : |
21.01.2008 |
|
Date of Ceasing : |
24.02.2010 |
|
|
|
|
Name : |
Ms. Prerna Suneja |
|
Designation : |
Secretary |
|
Address : |
R Block, 75G, |
|
Date of Birth/Age : |
20.10.1984 |
|
Date of Appointment : |
02.03.2010 |
|
|
|
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
AS ON 27.09.2010
|
Names of Shareholders |
|
No. of Shares |
|
Sanjeev Jain |
|
343275 |
|
Sandeep Jain |
|
447425 |
|
Lata Jain |
|
135075 |
|
Lata Jain J / W Umang Jain |
|
50 |
|
Kiran Jain J / W Sandeep Jain |
|
1800 |
|
Kiran Jain J / W Sanjeev Jain |
|
1800 |
|
D C Jain and sons HUF J/W Sanjeev Jain |
|
85000 |
|
D C Jain and son HUF J/W Sandeep Jain |
|
85000 |
|
Sanjeev Jain And Sons HUF |
|
22000 |
|
Sandeep Jain And Sons HUF |
|
52975 |
|
Sanjeev Jain J/W Arushi Jain |
|
300 |
|
Sandeep Jain J/W Kanishk Jain |
|
300 |
|
|
|
|
|
Total |
|
1175000 |
AS ON 27.09.2010
|
Equity Share Breakup |
|
Percentage of Holding |
|
Category |
|
|
|
Directors
or relatives of directors |
|
100.00 |
|
Total |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturer and Supplier of Pharmaceutical Machinery. |
|
|
|
|
Products: |
Pharmaceutical Machinery |
GENERAL INFORMATION
|
Customers : |
· ABBOTT India Limited · Cipla Limited · Alembic Limited · Blue Cross Laboratories Limited · FDC Limited · INTAS Pharmaceuticals Limited · Lupin Limited · Mankind Pharma Private Limited · Micro Labs Limited · Orchid Healthcare · Modi Mundi · Venus Remedies Limited · Shreya Life Science Private Limited |
|||||||||||||||
|
|
|
|||||||||||||||
|
No. of Employees : |
Not Available |
|||||||||||||||
|
|
|
|||||||||||||||
|
Bankers : |
·
State Bank of ·
ICICI Bank Limited, · Standard Chartered Bank, Credit Risk Control, Narain Manzil, 23 Barakhamba Road, New Delhi-110001, Delhi, India. |
|||||||||||||||
|
|
|
|||||||||||||||
|
Facilities : |
|
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Anil Jain D.D and Company Chartered Accountants |
|
Address : |
611, |
|
Tel. No.: |
91-11-23765494/23765495 |
|
|
|
|
Associates/Subsidiaries : |
|
CAPITAL STRUCTURE
AS ON 31.03.2010
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
1200000 |
Equity Shares |
Rs.10/- each |
Rs.12.000 Millions |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
1175000 |
Equity Shares |
Rs.10/- each |
Rs.11.750
Millions |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
11.750 |
11.750 |
11.750 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
2165.538 |
1762.562 |
1339.358 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
2177.288 |
1774.312 |
1351.108 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
912.451 |
947.393 |
917.284 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
912.451 |
947.393 |
917.284 |
|
|
DEFERRED TAX LIABILITIES |
123.166 |
86.992 |
36.099 |
|
|
|
|
|
|
|
|
TOTAL |
3212.905 |
2808.697 |
2304.491 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
1778.659 |
1490.230 |
1212.158 |
|
|
Capital work-in-progress |
3.668 |
18.331 |
206.987 |
|
|
|
|
|
|
|
|
INVESTMENT |
5.650 |
4.250 |
0.000 |
|
|
DEFERREX TAX ASSETS |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
740.858
|
604.662
|
510.839 |
|
|
Sundry Debtors |
971.171
|
909.072
|
638.931 |
|
|
Cash & Bank Balances |
55.847
|
95.177
|
3.021 |
|
|
Other Current Assets |
0.000
|
0.000
|
0.000 |
|
|
Loans & Advances |
372.131
|
271.835
|
261.290 |
|
Total
Current Assets |
2140.007
|
1880.746
|
1414.081 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
540.839
|
461.943
|
428.585 |
|
|
Other Current Liabilities |
76.636
|
61.601
|
35.900 |
|
|
Provisions |
97.604
|
61.316
|
64.250 |
|
Total
Current Liabilities |
715.079
|
584.860
|
528.735 |
|
|
Net Current Assets |
1424.928
|
1295.886
|
885.346 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
3212.905 |
2808.697 |
2304.491 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
4109.311 |
3774.502 |
3285.793 |
|
|
|
Other Income |
74.851 |
58.646 |
23.578 |
|
|
|
TOTAL (A) |
4184.162 |
3833.148 |
3309.371 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Raw material consumed |
2980.364 |
2688.148 |
2476.516 |
|
|
|
Manufacturing expenses |
133.719 |
113.841 |
56.224 |
|
|
|
Personnel expenses |
317.391 |
287.573 |
197.239 |
|
|
|
Administrative Expenses |
73.141 |
73.141 |
20.094 |
|
|
|
|
|
|
2750.073 |
|
|
|
Increase / Decrease in stock |
7.012 |
5.385 |
(43.099) |
|
|
|
TOTAL (B) |
3511.627 |
3168.088 |
2706.974 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
672.535 |
665.060 |
602.397 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
65.328 |
112.817 |
46.823 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
607.207 |
552.243 |
555.574 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
72.808 |
64.247 |
25.455 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
534.396 |
487.996 |
530.118 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
131.420 |
51.761 |
21.417 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
402.976 |
436.235 |
508.701 |
|
|
|
|
|
|
|
|
|
Add |
BALANCE
CARRIED TO THE B/S |
402.976 |
420.205 |
508.701 |
|
|
|
|
|
|
|
|
|
|
TOTAL EARNINGS
IN FOREIGN CURRENCY |
28.900 |
51.732 |
-- |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
342.96 |
371.26 |
382.09 |
|
KEY RATIOS
|
PARTICULARS |
|
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
PAT / Total Income |
(%) |
9.63
|
11.38
|
15.37 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
13.00
|
12.93
|
16.13 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
13.64
|
14.48
|
20.18 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.25
|
0.27
|
0.39 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
0.74
|
0.86
|
1.07 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
2.99
|
3.21
|
2.67 |
LOCAL AGENCY FURTHER INFORMATION
FORM 8
|
Corporate
identity number of the company |
U24239DL2004PLC125888 |
|
Name of the
company |
AKUMS DRUGS AND PHARMACEUTICALS
LIMITED |
|
Address of the
registered office or of the principal place of business in |
304, Email Id : legal@akums.net |
|
This form is for |
Modification
of charge |
|
Charge
identification (ID) number of the charge to be modified |
10050600 |
|
Type of charge |
|
|
Particular of charge
holder |
State bank of Email Id :
pandevijay@yahoo.co.in |
|
Nature of
instrument creating charge |
(i) Agreement of Hypothecation
of goods and Assets Form C-2 (ii) Letter
Regarding the grant of Individual Limits within the overall limit Form- C-5 (iii) Copy of
Recital Enhancement |
|
Date of
instrument Creating the charge |
27.01.2011 |
|
Amount secured by
the charge |
Rs.1250.000
Millions |
|
Brief of the
principal terms an conditions and extent and operation of the charge |
Rate of interest Interest CC @ 4%
above SBBR , present effective rate is @12.00% SLC 5% above
SBBR, present effective rate is @13.00% p.a. Terms of
Repayment As per agreement. Margin Raw
Materials-25%, Finished good-25%, Stock in process-25%, Book
Debts/receivables(upto 90 days)- 25% and Letter of credit & BG -20%. Extent and operation of the charge 100% Others The above is to
secure the credit facilities of Rs 1250.000 Millions i.e. CC (Stocks)
Rs.1000.000 Millions with CC(B/D) sub limit within CC(Stock) (Rs. 600.000
Millions), LC of Rs 100.000 Millions,
BG Rs 100.000 Millions and SLC Rs 50.000 Millions, granted by the Bank
to the company. |
|
Short particulars
of the property or asset(s) charged (including complete address and location
of the property) |
Primary Security:
WC : (i) First charge over the current assets at company's head office units I,
II and III including stocks and receivables both present and future. However,
first charge over the current assets of unit IV is with SCB. Collateral
Security: (i) Extension of charge on the fixed assets of the company both
present and future including Equitable Mortgage of factory land and building
situated at (a) Plot No.
19,20,21, Sector-6A, IIE, Ranipur, Haridwar, (b) Plot No. 22,
Sector-6A, IIE, Ranipur, Haridwar, (c) Plot No.
2,3,4 &5, Sector-6B, IIE, Ranipur, Haridwar, |
|
Date of
instrument modifying the charge |
26/06/2010 |
|
Particulars of
the present modification |
Total various
credit facilities enhanced from Rs 840.000 Millions to Rs.1250.000 Millions
as under :- CC( Stocks ) Rs. 1000.000 Millions CC( Book-debts
) Rs.(600.000) Millions with in the
CC stocks limit SLC Rs.50.000 Millions Letter of credit
of Rs.100.000 Millions Bank Guarantee of
Rs.100.000 millions Total Rs.1250.000 millions Other terms and
conditions remain the same. |
|
|
|
Fixed Assets:
¨
¨ Building
¨ Plant And Machinery
¨ Electrical Installation
¨ R And D And Laboratory Equipments
¨ Pollution Control Equipment
¨ Office Equipments
¨ Furniture And Fixtures
¨ Vehicles
AS PER WEBSITE DETAILS:
Profile:
Subject was established and formed in the year 2004 by Shri
D.C. Jain, Shri Sanjeev Jain and Shri Sandeep Jain, the Promoter Director.
Mr.D.C. Jain is a well knit combination of a professional, entrepreneur and
Industrialist.
Mr. D.C. Jain had been President of the Institute of Company Secretaries of India and has over three decades of experience as top Executive and Industrialist. His experience includes Manufacturing and Marketing of Pharmaceutical Formulations.
Company started with the small capital of Rs. 11.75 millions and in a short span of time, the shareholders fund has grown to Rs. 1246.45 millions.
During the financial year 2004-2005, the Company purchased land, arranged funds, constructed buildin.3gs, installed machines, engaged technical persons, made arrangements for Water, Power, Effluent Treatment, obtained pollution control licenses, Drugs Manufacturing Licenses, etc. got the manufacturing facilities approved from various big pharma companies, obtained orders, made trial runs and came into commercial production in the year of its incorporation.
There are problems for persons who are first start ups; but satisfaction is great. Company could see the "Plan" converted into "Plant" in its first year. "Plant" sown could turn into a "Tree" and started giving "Fruits", in the year of Incorporation.
After incorporation in the year 2004, Company obtained necessary Licenses, Permissions and Approvals from Government and Commenced Productions in the same year of Incorporation. Akums started its Plant No. 1 with manufacturing Tablets and Capsules in both Beta and Non Beta Lactum Sections.
Quality products, timely delivery, reasonable prices, transparency and honesty in dealings made subject is a popular manufacturing company amongst multinational and big pharmaceutical houses of India and abroad.
Company developed a good customer base with limited dosage form of Tablets, Capsules, Dry Syrups and Liquid Orals. The demand from its valued customers for good quality injections, ear/eye drops, Low RH Preparations like Clavulanic acid, powder in sachets, soft gelatin capsule, FFS Technology based preparations, pre-filled Syringes lead to the expansion of its existing capacities and diversification into other dosage forms . Two new facilities of International Standards were therefore set up and became operational in 2007-2008. Setting of a project is not a one man show but the total accomplishment had been a result of excellent team work of all the personnel working with subject.
PROFESSIONAL
MANAGEMENT AND TEAM SPIRIT
Subject is professionally managed by the Board of Directors which is assisted by a team of Qualified and experienced professional executives. The intelligence, imagination, knowledge, education and experience of the promoters create the mission for the organization and it is the wisdom and effectiveness of the corporate personnel which translates their vision into reality and converts the resources into results. Subject Team of People, Work with Dedication, Diligence, Devotion, Determination, Dynamism, Discipline and Direction.
Board
of Directors:
Mr. D.C.Jain - FOUNDER of AKUMS DRUGS and PHARMACEUTICALS LIMITED
The major source for the Idea of setting up a Pharmaceutical Manufacturing Company is Mr. D.C.Jain. He thought of setting up a project where none other existed. Selection of area of tax free zone, selection of best buyers, likely future demand of the products required to be tapped; and the limited resources to be converted into desired success.Mr. D.C.Jain knew that Setting up of Industry in the hilly areas had a better viability, because of certain exemptions in excise and income tax; but there was lack of Industrial Environment, additional administrative costs, additional cost of transportation also.
Mr.D.C.Jain
developed his unique characteristics for Business:
¨ Innovative formulations
¨
New Drug Approvals - some of them first time in
¨ Manufacturer of top ORG brands
¨
Sound Customer Base - almost all top Pharma
companies of
¨ Sophisticated and ultra modern manufacturing facility with largest capacity.
¨ Own R and D and F and D
¨ Service and Satisfaction to customers
¨ Professional Management with dedicated technical and non-technical employees
¨ Honest and transparent dealings
¨
As an early Starter, Mr. D.C.Jain's first challenge was to
set up the units for the services of pharma industry.
After incorporation, Subject arranged
funds, purchased land, constructed building, purchased and installed machines,
engaged technical persons, made arrangements for Water, Power, Effluent
Treatment, obtained pollution control licenses, Drugs Manufacturing Licenses
and also got the manufacturing facilities approved from various big
pharmaceutical companies.
Under the Leadership of Mr.D.C.Jain Company could see the "Plan"
converted into "Plant" in its first year.
The firmness, the determination, a goal achieving, a resolution to start
factory production in the first year itself and the success of an organization
was a team effort under the able guidance of Mr. D.C.Jain In short span of five
years;
¨
AKUMS growth of Plan to Plants
¨
AKUMS became Icon of India's Healthcare
¨
AKUMS gave a new direction to pharmaceutical industry by providing
unique innovative products
¨
Addition of one new unit each year
¨
It was the entrepreneur exercises of Mr.D.C.Jain and his
sense of adventure, vision, passion, creativity, courage, endurance,
originality, innovation, determination, leadership and hard work, with the team
of his people for accomplishment of the task and to convert his vision into
realities.
Dr. SANJEEV JAIN
Dr. Sanjeev Jain, is a Graduate in Medical Sciences with Post Graduation in Management (M.B.A.) He is also the Associate Member of the All India Management Association and Delhi Management Association. He has a vast experience of nearly 25 years in the field of sales and marketing of pharmaceuticals. Dr. Sanjeev Jain had been awarded order of Merit for Management and also got honored With SAMAJ SHREE recognition for rendering persistent services to the public.
Starting his career at an age of 17 years in wholesale trading business of
medicines, Dr. Jain had an astounding progress. With in a in a short period of 5
years he could visualize setting up of own manufacturing unit. He is one of the
Promoter Directors of Akums Drugs and Pharmaceuticals Ltd. He has been
instrumental in setting up the Company, which today is very well known as
manufacturer of quality drugs at affordable Prices for Domestic as well as
International Market.
Under the Able Guidance and Leadership of Dr. Sanjeev Jain, AKUMS has reached
to enviable Position in the Health Care Industry. It is because of his hard
work, enterprising spirit and business acumen that AKUMS Achieves Newer and
Newer Heights Day After Day.
Under his Dynamic Professional Approach, the Company made several International
collaborations and made study Progress in Its Global Presence. A person with a
humble heart Dr. Sanjeev Jain donates generously to noble cause, helps
community and gives his time unhesitatingly to social services and public weal.
Dr. Sanjeev Jain combines in himself dynamism, dedication, diligence, devotion,
determination, discipline and direction. With his education, knowledge and
experience, he knows how to plan, set goals, bring plans into effectiveness and
translate the actions into results.
MR. SANDEEP JAIN
Mr. Sandeep Jain Commerce and Law Graduate (B.Com.LL.B.) with Post Graduation in Management (M.B.A.) F.M.S.P.I., A.M.I.M.A, is a self-made industrialist with nearly 25 years of matured experience in the field of pharmaceuticals specially the production, quality assurance and plant management. He is also a fellow member of AIMA.
Mr. Sandeep Jain is one of the Promoter Director of Akums Drugs and Pharmaceuticals Limited an internationally recognized WHO-GMP, ISO 9001:2000 and ISO 14001:2004 Company. With his strenuous efforts the Company received various National and International Recognitions, Quality Certificates and also entered into Joint Venture with International Companies.
Some of the
unique achievements of Mr. Sandeep Jain are -
¨ He had been an elected member of the Managing Committee of the PHD Chamber and continues to be active member of its various Committees.
¨ Joint Secretary of Rajasthan Pharmaceutical Manufacturers Association; and Executive Member and Vice-President of Bhiwadi Manufacturers Association.
¨ Presently General Secretary Association of Dev Bhumi Pharma Industries, Haridwar and Vice- President of SIDCUL Manufacturers Association, Haridwar.
¨ He is also actively associated with many trade and commercial Organizations.
Mr. Sandeep Jain has been awarded several prestigious awards
like Gold Medal for Management Order for Merit Award, SAMAJ SHREE Award for
Excellence in Management, Outstanding Personality award 1998 and Man of the
Year 1999 award in recognition of his outstanding contribution to industrial
growth, social commitment and excellence in his field of activity.Mr. Sandeep
Jain is also associated with prominent academic, social and welfare
organizations like Rotary Club, Lions Club, S.S. Jain Sabha and Maharaja
Agarsen Aggarwal society.Mr. Sandeep Jain believes in coordinated, concerted
and co-operated efforts of all team members, which makes them to win and
succeed. Mr.Jain knows how to utilize wisdom and effectiveness of his
colleagues on the Management Committee.
DR. SANTOSH K. TALWAR
Dr. Santosh K. Talwar one of the Directors is an adviser to
DFID (Department of International Development of U.K.), a British Government
Agency funding for Reproduction and Child Healthcare Programs. Dr. Santosh K.
Talwar had retired as Director of Central Indian Pharmacopoeia Laboratory
(CIPL),
Dr. Talwar has
Core Competence in the following areas :
¨ Regulatory, Quality Assurance, Control principles in Drugs and Pharmaceuticals.
¨ Strong qualifications in general management in regulatory environment, strategic planning and implementation such as Calibration, Software implementation, Document Control System including LIMS.
¨ Expert in Protocol Development of new molecules, Impurity Profiling, Method Development and Validation as per ICH guidelines.
¨ Skilled Professional in lab designing, equipments and lab operations as per cGLP norms.
¨ Acknowledged technical auditor under cGMP/cGLP/GCP regime.
¨ Expert Faculty in all Pharmaceutical Analysis including techniques, practices, methods and Pharmacopoeia related issues.
He is also having professional experience as WHO Consultant
and had been working in Regional Drugs Testing Laboratory, Chandigarh, National
Institute of Pharmaceutical Education and Research, Mohali. Dr. Santosh K.
Talwar has many publications and research papers to his credit.
Mr. N.D. Sachdeva , B. Pharma (Hons.) has more than 34 years
of experience in Drug Manufacturing Operations,Quality Control and Quality
Assurance. He has vast practical exposure of various Forms of pharmaceutical such
as Tablets, Syrups, Capsules, Ointment and external applications etc. He is a
manufacturing chemist from the Drugs Control Department,
Mr. N.D. Sachdeva is a
Whole-time Director of Akums Drugs and Pharmaceuticals Limited and he looks after
the day to day affairs of the factory Operations including :
¨ Production and quality controls; development, implementation and maintenance of systems, procedures and records for Quality Management System, GMP norms, Standard Operating Procedures, Work Instructions; etc
¨ Compliance with regard to Act, Rules, Notifications, Circulars etc. relating to Drugs and Cosmetics Act, 1940; Drugs Licensing, products approval and liaisoning with the Drugs Department(s).
MR. M.P. SINGH
Mr. M.P. Singh, B.A., LL.B. and a Diploma Holder in Personnel Management is Whole Time Director of the Company. He has nearly Twenty five years experience in Factory Management, Personnel and General Administration of which more than eight years in Pharmaceutical Companies.
Mr. M.P.
Singh looks after the day-to-day Legal Affairs, General Administration and
Management and Commercial Matters of company's factory including matters
related to :
¨ Factories Act, Labour Laws, Pollution Control
¨ Formulation and development of personnel policies;
¨ General administration of the works, security and safety of the Factory; safe custody of Company properties and premises.
¨ Excise, Sales Tax, Income Tax, Service Tax, matters and liaison with Government offices.
MANAEMENT DISCUSSION
AND A ALSLS {2009-10)
INDUSTRY STRUCTURE
AND DEVELOPMENT
Indian Pharmaceutical industry ranks very high in the third world in terms of technology, quality and range of medicines manufactured. It is estimated to be worth $ 18 Billion, growing at about 155% percent annually. Also, while the Indian sector represents just 8 percent of the global industry totaI by volume. putting it n fourth place worldwide, It accounts For 13 percent by value; and it8 drug exports have beer growing 30 percent annually Today, this industry is n the front rank of India’s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology.
The Indian pharmaceutical sector being highly fragmented has
more than 20,000 registered units; and faces severe price competition apart
from government price control.
The Pharma industry has grown exponentially in the last two decades. India’s pharmaceutical sector Is currently undergoing unprecedented change Much of this is due to the country% introduction, on 1anury 1, 2005, of a system of product patents, before that, only patents for processes were permitted to be issued, a fact that has been instrumental in the cosmetic industry’s huge success as a worldwide exporter of high quality genetic drugs. The market is projected to grow at a very high pace between fiscal 2009 -2020 as the leading Indian pharmaceutical companies strive towards International competitiveness.
OUTLOOK
The company dedicates itself to humanities quest for longer, Healthier and happier Life. The priority is to focus on products and services across the globe, Through Excellence in technology, based on world-class research and development ultimately achieving leadership in chosen markets.
Subject has excellent future and we are expecting a growth rate to the India’s pharma growth, company has six plants out which three are fully functional one more plant for oncology is proposed in financial year 2011-12. The company wants to lead the world of Manufacturing of Pharmaceuticals.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market survey
revealed that the amount of compensation sought by the subject is fair and
reasonable and comparable to compensation paid to others for similar services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.46.38 |
|
|
1 |
Rs.74.01 |
|
Euro |
1 |
Rs.64.48 |
j
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
5 |
|
PAID-UP CAPITAL |
1~10 |
6 |
|
OPERATING SCALE |
1~10 |
7 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
7 |
|
--PROFITABILIRY |
1~10 |
7 |
|
--LIQUIDITY |
1~10 |
7 |
|
--LEVERAGE |
1~10 |
6 |
|
--RESERVES |
1~10 |
7 |
|
--CREDIT LINES |
1~10 |
6 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
YES |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
YES |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
58 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.